CRL
Neutral signalScored 2026-10-26 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Charles River Laboratories International, Inc.
- Nom
- Charles River Laboratories International, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NYSE
- Capitalisation
- $16.6B
- Employés
- 19,000
- PDG
- Birgit Girshick
- Site web
- https://www.criver.com
- Marché
- CERTGNNSFHNGZYICLRMEDPWUXIF
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 24 042 titres (~8 414 700,00 $ US)
- Insiders
- FOSTER JAMES C
- Total bought
-
—
Avg buy (VWAP, 90d window) $297.43 vs last close $357.27 (+20.1%)
- Total sold
-
$25,174,103
Avg sell (VWAP, 90d window) $286.19 vs last close $357.27 (+24.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$23,057,271 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-22
- Liquidity
- Liquid $394,459,199/day · 20d vol
- Last synced
-
2026-10-26 22:35:44
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-21 | Parisotto Shannon M | Sell · S | 2,156 | $344.41 | $742,548 | Form 4 |
| 2026-10-05 | Parisotto Shannon M | Sell · S · 10b5-1 | 981 | $308.44 | $302,580 | Form 4 |
| 2026-09-30 | Coleman Glenn | Buy · P | 10 | $297.43 | $2,974 | Form 4 |
| 2026-08-25 | FOSTER JAMES C | Sell · S · 10b5-1 | 33,561 | $300.00 | $10,068,300 | Form 4 |
| 2026-08-19 | Parisotto Shannon M | Sell · S · 10b5-1 | 2,039 | $294.12 | $599,711 | Form 4 |
| 2026-08-18 | Andrews Nancy C | Sell · S | 573 | $285.24 | $163,443 | Form 4 |
| 2026-08-11 | Girshick Birgit | Sell · S · 10b5-1 | 6,500 | $279.90 | $1,819,350 | Form 4 |
| 2026-08-11 | Parisotto Shannon M | Sell · S · 10b5-1 | 3,714 | $279.66 | $1,038,657 | Form 4 |
| 2026-08-10 | FOSTER JAMES C | Sell · S · 10b5-1 | 28,733 | $275.00 | $7,901,575 | Form 4 |
| 2026-08-06 | Creamer Victoria L | Sell · S | 4,179 | $259.16 | $1,083,030 | Form 4 |
| 2026-08-06 | Knell Michael Gunnar | Sell · S | 482 | $265.17 | $127,812 | Form 4 |
| 2026-08-05 | Parisotto Shannon M | Sell · S · 10b5-1 | 5,046 | $263.00 | $1,327,098 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-08 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-08 | Robert P. Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-01-15 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-25 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2022-08-25 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-09-30 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2019-10-08 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2019-10-07 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2019-08-29 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2018-09-26 | Lamar Seeligson Smith | Sale (Full) | $1,001 - $15,000 |
| 2018-09-19 | Thomas Charles MacArthur | Purchase | $1,001 - $15,000 |
| 2018-09-13 | Thomas Charles MacArthur | Purchase | $1,001 - $15,000 |
| 2018-09-12 | Thomas Charles MacArthur | Purchase | $1,001 - $15,000 |
| 2018-09-11 | Thomas Charles MacArthur | Purchase | $1,001 - $15,000 |
| 2018-07-26 | Lamar Seeligson Smith | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-26 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
CRL presents a deeply deteriorated fundamental profile — net losses in 2025, a debt-to-EBITDA of 6.94x, and declining interest coverage — that materially undermines the moderate catalyst score of 55.
The first sentence of the analysis written for CRL on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 1.29 · operating margin 13%
Suggested stop 260.56, nearest stored support minus 0.5 ATR(27.1% under the last close). Research, not advice. Not an order.
Recent news
- 2026-10-26 Ariel Fund Q3 2026 Leaders And Laggards ZBRA''s revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL''s results reflected improving demand across biopharma and biotechnology customers. Bio-Rad''s shares also benefited from the announcement of a broad restructuring program designed to streamline operations and enhance profitability.
- 2026-10-22 Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs.
- 2026-10-15 Charles River Laboratories International (NYSE:CRL) Share Price Crosses Above 200 Day Moving Average – Should You Sell? Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report)''s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $226.13 and traded as high as $310.53. Charles River Laboratories International shares last traded at $302.7710, with a volume of 941,309
- 2026-10-13 Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River''s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r.
- 2026-10-09 Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.
- 2026-10-07 PGNY or CRL: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
- 2026-10-07 Charles River Gains 75.8% in a Year: What''s Driving the Rally? CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.
- 2026-10-06 Charles River and Autolomous Partner to Transform Laboratory Execution Systems WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River''s Apollo® platform that connects and digitizes laboratory execution, built on Autolomous''s autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River''s strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches.
- 2026-09-30 Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Price Target of $290.00 According to Analysts Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given
- 2026-09-25 Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan Charles River Laboratories International NYSE: CRL outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin and low-double-digit non-GAAP earnings-per-share growth.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-27 | 2024-12-28 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 30.5% | 32.9% | 36.4% | 36.8% | 37.7% | |
| Ebit Margin | 0.2% | 5.4% | 17.4% | 17.2% | 15.7% | |
| Ebitda Margin | 10.2% | 14.3% | 25.0% | 24.8% | 23.2% | |
| Operating Profit Margin | 12.6% | 5.6% | 14.9% | 16.4% | 16.7% | |
| Pretax Profit Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | |
| Continuous Operations Profit Margin | -3.5% | 0.6% | 11.6% | 12.4% | 11.3% | |
| Net Profit Margin | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | |
| Bottom Line Profit Margin | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | |
| Current Ratio | 1.292 | 1.411 | 1.525 | 1.318 | 1.233 | |
| Quick Ratio | 1.025 | 1.131 | 1.164 | 1.084 | 1.040 | |
| Solvency Ratio | 0.066 | 0.093 | 0.174 | 0.173 | 0.148 | |
| Cash Ratio | 0.191 | 0.196 | 0.262 | 0.214 | 0.237 | |
| Price To Earnings Ratio | -69.986 | 930.800 | 25.502 | 22.769 | 48.492 | |
| Price To Earnings Growth Ratio | 0.045 | -9.513 | -8.135 | 0.983 | 8.486 | |
| Forward Price To Earnings Growth Ratio | 0.045 | -9.513 | -8.135 | 0.983 | 8.486 | |
| Price To Earnings Diluted Ratio | -69.986 | 930.800 | 25.640 | 22.985 | 49.576 | |
| Price To Earnings Diluted Growth Ratio | 0.045 | -9.514 | -9.349 | 0.929 | 8.924 | |
| Price To Book Ratio | 3.190 | 2.763 | 3.367 | 3.720 | 7.476 | |
| Price To Sales Ratio | 2.514 | 2.362 | 2.933 | 2.785 | 5.353 | |
| Price To Free Cash Flow Ratio | 19.468 | 19.068 | 33.145 | 37.544 | 35.617 | |
| Price To Operating Cash Flow Ratio | 13.684 | 13.021 | 17.707 | 17.868 | 24.907 | |
| Debt To Assets Ratio | 0.430 | 0.362 | 0.374 | 0.407 | 0.456 | |
| Debt To Equity Ratio | 0.969 | 0.787 | 0.853 | 1.041 | 1.265 | |
| Debt To Capital Ratio | 0.492 | 0.440 | 0.460 | 0.510 | 0.558 | |
| Long Term Debt To Capital Ratio | 0.446 | 0.393 | 0.424 | 0.476 | 0.535 | |
| Financial Leverage Ratio | 2.255 | 2.175 | 2.278 | 2.554 | 2.771 | |
| Working Capital Turnover Ratio | 10.916 | 8.415 | 9.166 | 13.516 | 11.756 | |
| Operating Cash Flow Ratio | 0.658 | 0.739 | 0.648 | 0.568 | 0.736 | |
| Operating Cash Flow Sales Ratio | 0.184 | 0.181 | 0.166 | 0.156 | 0.215 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.703 | 0.683 | 0.534 | 0.476 | 0.699 | |
| Debt Service Coverage Ratio | 2.190 | 4.065 | 6.812 | 14.433 | 9.975 | |
| Interest Coverage Ratio | 4.745 | 1.800 | 4.515 | 10.979 | 7.981 | |
| Short Term Operating Cash Flow Coverage Ratio | 12.081 | 0.000 | 0.000 | 0.000 | 7,532.663 | |
| Operating Cash Flow Coverage Ratio | 0.241 | 0.270 | 0.223 | 0.200 | 0.237 | |
| Capital Expenditure Coverage Ratio | 3.366 | 3.153 | 2.147 | 1.908 | 3.326 | |
| Dividend Paid And Capex Coverage Ratio | 3.366 | 3.153 | 2.147 | 1.908 | 3.326 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 31.511 | 20.811 | 14.436 | 14.131 | 26.714 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 30.5% | ▼-2.4% | ▼-4.3% |
| Ebit Margin | 0.2% | ▼-5.2% | ▼-11.0% |
| Ebitda Margin | 10.2% | ▼-4.1% | ▼-9.3% |
| Operating Profit Margin | 12.7% | ▲7.0% | ▼-0.6% |
| Pretax Profit Margin | -2.5% | ▼-4.8% | ▼-11.1% |
| Continuous Operations Profit Margin | -3.5% | ▼-4.2% | ▼-10.0% |
| Net Profit Margin | -3.6% | ▼-3.9% | ▼-9.9% |
| Bottom Line Profit Margin | -3.6% | ▼-3.9% | ▼-9.9% |
| Current Ratio | 1.292 | ▼-0.120 | ▼-0.064 |
| Quick Ratio | 1.025 | ▼-0.106 | ▼-0.064 |
| Solvency Ratio | 0.066 | ▼-0.026 | ▼-0.065 |
| Cash Ratio | 0.191 | ▼-0.005 | ▼-0.029 |
| Price To Earnings Ratio | -69.986 | ▼-1000.786 | ▼-261.502 |
| Price To Earnings Growth Ratio | 0.045 | ▲9.558 | ▲1.672 |
| Forward Price To Earnings Growth Ratio | 0.045 | ▲9.558 | ▲1.672 |
| Price To Earnings Diluted Ratio | -69.986 | ▼-1000.786 | ▼-261.789 |
| Price To Earnings Diluted Growth Ratio | 0.045 | ▲9.559 | ▲1.838 |
| Price To Book Ratio | 3.190 | ▲0.426 | ▼-0.913 |
| Price To Sales Ratio | 2.514 | ▲0.152 | ▼-0.675 |
| Price To Free Cash Flow Ratio | 19.468 | ▲0.400 | ▼-9.500 |
| Price To Operating Cash Flow Ratio | 13.684 | ▲0.663 | ▼-3.753 |
| Debt To Assets Ratio | 0.430 | ▲0.068 | ▲0.024 |
| Debt To Equity Ratio | 0.969 | ▲0.182 | ▼-0.014 |
| Debt To Capital Ratio | 0.492 | ▲0.052 | ▼-0.000 |
| Long Term Debt To Capital Ratio | 0.446 | ▲0.053 | ▼-0.009 |
| Financial Leverage Ratio | 2.255 | ▲0.080 | ▼-0.152 |
| Working Capital Turnover Ratio | 10.916 | ▲2.501 | ▲0.162 |
| Operating Cash Flow Ratio | 0.658 | ▼-0.081 | ▼-0.011 |
| Operating Cash Flow Sales Ratio | 0.184 | ▲0.002 | ▲0.003 |
| Free Cash Flow Operating Cash Flow Ratio | 0.703 | ▲0.020 | ▲0.084 |
| Debt Service Coverage Ratio | 2.190 | ▼-1.874 | ▼-5.305 |
| Interest Coverage Ratio | 4.745 | ▲2.945 | ▼-1.259 |
| Short Term Operating Cash Flow Coverage Ratio | 12.081 | ▲12.081 | ▼-1496.868 |
| Operating Cash Flow Coverage Ratio | 0.241 | ▼-0.029 | ▲0.006 |
| Capital Expenditure Coverage Ratio | 3.366 | ▲0.213 | ▲0.586 |
| Dividend Paid And Capex Coverage Ratio | 3.366 | ▲0.213 | ▲0.586 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 31.511 | ▲10.700 | ▲9.990 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.09B | $9.56B | $12.11B | $11.07B | $18.95B | |
| Enterprise value | $12.95B | $12.09B | $14.90B | $13.94B | $21.91B | |
| EV / Sales | 3.22x | 2.99x | 3.61x | 3.50x | 6.19x | |
| EV / Op. cash flow | 17.55x | 16.46x | 21.79x | 22.49x | 28.80x | |
| EV / Free cash flow | 24.97x | 24.11x | 40.78x | 47.25x | 41.18x | |
| EV / EBITDA | 31.51x | 20.81x | 14.44x | 14.13x | 26.71x | |
| Net debt / EBITDA | 6.94x | 4.35x | 2.70x | 2.90x | 3.61x | |
| Current ratio | 1.29x | 1.41x | 1.52x | 1.32x | 1.23x | |
| Income quality | -5.19x | 29.05x | 1.42x | 1.26x | 1.91x | |
| Graham number | — | $17 | $121 | $112 | $94 | |
| Graham net-net | -$61 | -$61 | -$68 | -$72 | -$72 | |
| Tax burden | 145.1% | 11.1% | 81.7% | 78.0% | 81.3% | |
| Interest burden | -1322.1% | 42.4% | 81.0% | 91.3% | 86.7% | |
| Working capital | $326.7M | $409.0M | $553.6M | $347.4M | $240.9M | |
| Invested capital | $5.45B | $6.00B | $6.55B | $6.01B | $5.60B | |
| Return on assets | -2.0% | 0.1% | 5.8% | 6.4% | 5.6% | |
| Operating ROA | 6.9% | 2.9% | 7.8% | 8.9% | 9.4% | |
| Return on tangible assets | -3.6% | 0.3% | 11.2% | 12.8% | 12.0% | |
| Return on equity | -4.6% | 0.3% | 13.2% | 16.3% | 15.4% | |
| Return on invested capital | 8.4% | 0.9% | 7.1% | 7.9% | 8.1% | |
| Return on capital employed | 8.4% | 3.5% | 8.6% | 10.0% | 9.8% | |
| Earnings yield | -1.4% | 0.1% | 3.9% | 4.4% | 2.1% | |
| Free cash flow yield | 5.1% | 5.2% | 3.0% | 2.7% | 2.8% | |
| Capex / Op. cash flow | 29.7% | 31.7% | 46.6% | 52.4% | 30.1% | |
| Capex / Depreciation | 54.3% | 64.4% | 101.4% | 106.9% | 86.2% | |
| Capex / Sales | 5.5% | 5.8% | 7.7% | 8.2% | 6.5% | |
| SG&A / Sales | 18.5% | 18.5% | 18.1% | 16.7% | 17.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.8% | 1.7% | 1.7% | 1.9% | 2.0% | |
| Intangibles / Total assets | 43.5% | 47.4% | 48.3% | 50.0% | 53.7% | |
| Days sales outstanding | 64d | 65d | 69d | 69d | 67d | |
| Days payables outstanding | 19d | 19d | 23d | 30d | 33d | |
| Operating cycle | 104d | 102d | 122d | 106d | 100d | |
| Cash conversion cycle | 84d | 84d | 98d | 76d | 67d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years